AC Immune SA
ACIUHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AC Immune SA focuses on Biotechnology services and products. AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative. At a $234.1M market cap, AC Immune SA ranks as a micro-cap company within healthcare. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Market Cap
$234.1M
Beta
1.57
P/E (TTM)
—
P/E (Fwd)
3.77
EPS (TTM)
$-0.82
EPS (Fwd)
$0.61
ROE
-104.8%
ROA
-23.1%
Cash
$74.8M
Total Debt
$4.3M
Free CF
—
52W Change
-0.4%
Annual Financials
Cash vs Debt
Where ACIU stands vs its 150-day and 200-day moving averages
As of the June 30, 2026 close, ACIU finished 9.83% below its 150-day moving average ($2.95) and 10.74% below its 200-day moving average ($2.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACIU overbought or oversold?
At the June 30, 2026 close, ACIU's RSI(14) was 71.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $74.8M in cash and $4.3M in debt, ACIU maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Return on equity stands at -104.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.57 means ACIU is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AC Immune SA and its sector.